STOCK TITAN

Tonix Pharmaceut - TNXP STOCK NEWS

Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.

Overview

Tonix Pharmaceuticals Holding Corp (NYSE: TNXP) is a biopharmaceutical company dedicated to the development, licensing, and commercialization of innovative therapeutics designed to address significant public health challenges. With a deep-rooted focus on pharmaceutical innovation and clinical development, Tonix is committed to advancing treatments across multiple therapeutic areas including central nervous system (CNS) disorders, immunology, rare diseases, and infectious diseases. The company employs a comprehensive research and development strategy that is grounded in scientific rigor and a commitment to alleviating patient suffering through novel treatment options.

Core Business Operations

At its core, Tonix Pharmaceuticals is engaged in a dual approach that combines discovery, development, and commercialization within the competitive biopharmaceutical landscape. The company's operations are structured around three main areas:

  • Innovative Research and Clinical Development: Tonix pursues a robust pipeline of product candidates aimed at addressing critical unmet medical needs. Their efforts include the development of therapeutics for CNS disorders, such as PTSD and fibromyalgia, as well as cancer, autoimmunity, and transplant rejection through advanced biologics.
  • Product Commercialization: Through its subsidiaries, Tonix is focused on bridging the gap between research and market by licensing and promoting differentiated therapeutic modalities. The company has strategically acquired and developed non-oral treatment options, including fast-acting migraine therapies, to improve patient outcomes.
  • Strategic Partnerships and Licensing: Collaboration with healthcare providers and research institutions is central to the company's operations. By leveraging licensing agreements and joint ventures, Tonix extends its market reach while maintaining a strong emphasis on scientific excellence and regulatory compliance.

Therapeutic Areas & Pipeline

The company boasts a diverse portfolio catered to some of the most challenging diseases. In the realm of CNS disorders, Tonix has developed candidates such as Tonmya for PTSD, and other novel molecules designed to modulate central nervous system functions. Its immunology division focuses on biologics aimed at preventing allograft rejection and treating autoimmune diseases, with candidates like a humanized monoclonal antibody directed against CD40-ligand. The pipeline also includes product candidates targeting rare diseases and infectious diseases, reflecting the company’s commitment to tackling conditions that are often underserved by existing therapies.

Research & Development Strategy

Tonix Pharmaceuticals invests significantly in R&D as a core component of its business model. The company emphasizes:

  • Innovative Scientific Approach: Utilizing state-of-the-art research methodologies, Tonix seeks to create products that address the shortcomings of conventional therapies. This is illustrated by its development of non-oral formulations such as autoinjectors and nasal sprays, which bypass traditional absorption challenges associated with oral medications.
  • Comprehensive Clinical Evaluation: The company designs rigorous clinical trials aimed at ensuring the efficacy and safety of its product candidates. Such efforts are central to its strategy of addressing complex disorders where typical treatment pathways are inadequate.
  • Regulatory Engagement: By actively working with regulatory bodies, Tonix ensures that its development processes meet the highest standards. This careful attention to compliance reinforces the company’s dedication to establishing trusted treatment alternatives in the marketplace.

Competitive Landscape & Market Position

Operating as part of a broad, competitive biopharmaceutical market, Tonix Pharmaceuticals distinguishes itself through its focused approach on conditions that require innovation. The company’s emphasis on non-oral formulations for acute conditions, particularly in the treatment of migraine, sets it apart from traditional oral therapies that are often hindered by slower absorption and gastrointestinal complications. Additionally, its diversified pipeline allows it to address multiple segments of the market simultaneously, from CNS disorders to immunology and rare diseases. While competition is fierce, Tonix’s strategic emphasis on clinically validated innovation provides a strong counterbalance to established players.

Product Differentiation & Innovative Approach

Tonix’s portfolio is notable for its emphasis on speed, efficacy, and patient-centric solutions. For example, its development of non-oral options such as an autoinjector and nasal spray for migraine relief underscores its dedication to improving patient experiences by providing rapid and reliable treatment modalities. In addition, candidates designed for fibromyalgia and PTSD illustrate the company’s commitment to addressing complex, multi-faceted conditions with treatments that diverge from traditional pharmaceutical approaches.

Commitment to Public Health

In addressing some of the most challenging public health issues, Tonix Pharmaceuticals demonstrates a strong commitment to evolving patient care. By focusing on both acute and chronic conditions, the company not only alleviates suffering but also contributes to broad-based improvements in quality of life. Its strategic investments in clinically promising candidates exemplify a balanced approach that merges advanced scientific research with practical, market-driven initiatives.

Conclusion

Tonix Pharmaceuticals Holding Corp represents a dynamic and multifaceted biopharmaceutical enterprise aimed at addressing critical health challenges with innovative therapeutic solutions. Through a combination of focused research and strategic commercialization, Tonix maintains a robust pipeline that spans CNS disorders, immunology, rare diseases, and infectious conditions. The use of advanced scientific techniques and novel delivery methods enables the company to offer differentiated products that respond to the shortcomings of traditional treatments. With an operational model built on solid clinical research and a commitment to improving patient outcomes, Tonix remains a noteworthy participant within the competitive landscape of biopharmaceutical innovation.

Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced a 1-for-32 reverse stock split effective May 17, 2022. This measure aims to raise the per-share trading price to meet NASDAQ's minimum $1.00 bid price requirement for continued listing. The reverse split will reduce authorized shares from 1.6 billion to 50 million and will also affect outstanding warrants and stock options. Shareholders will not receive cash for fractional shares. The company is engaged in developing therapeutics for various diseases, including fibromyalgia and Long COVID.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.77%
Tags
none
-
Rhea-AI Summary

Tonix Pharmaceuticals (NASDAQ: TNXP) announced key developments and financial results for Q1 2022. The company initiated enrollment for its Phase 3 trial of TNX-102 SL for fibromyalgia, expecting interim results in Q1 2023. The FDA cleared the IND for TNX-102 SL targeting Long COVID, with a Phase 2 trial set to begin soon. Financially, Tonix reported $140 million in cash, down from $178 million at the end of 2021, with Q1 cash used for operations rising to $31 million. R&D expenses were $18.4 million, leading to a net loss of $26.4 million, or $0.05 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
-
Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) announced that its Chief Operating Officer, Jessica Morris, will present at the 2022 Q2 Investor Summit on May 4, 2022, at 11:00 a.m. ET in New York. Interested investors can arrange meetings with management through the conference coordinator. A webcast of the presentation will be accessible on Tonix's website under the IR Events tab. Tonix focuses on developing therapeutics across various sectors including immunology, infectious disease, and CNS disorders. The company plans to initiate several clinical trials for its pipeline products in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced that CEO Seth Lederman will present at B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 27, 2022, at 1:00 p.m. ET. A webcast will be available on the company’s website.

Tonix focuses on developing therapeutics for immunology, rare diseases, infectious diseases, and CNS conditions, with several investigational drugs in the pipeline, including TNX-1500 for autoimmune diseases and TNX-2900 for Prader-Willi syndrome, both expecting clinical trials in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced findings from a study involving over 50,000 Long COVID patients, revealing that over 40% exhibited fibromyalgia-like multi-site pain symptoms. The study highlights that 36% of these patients used opioids, a rate that increased with additional symptoms like fatigue and insomnia. The FDA has cleared an IND application for TNX-102 SL, which will enter a Phase 2 clinical trial targeting this specific symptom set in Long COVID. The trial is set to commence in the second quarter of 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present at NobleCon18, taking place from April 19-21, 2022, in Hollywood, Florida. Lederman's presentation is scheduled for April 21 at 9:30 a.m. ET in the Seminole Ballroom C of the Hard Rock Hotel & Casino. A webcast will be available on the Tonix website starting April 22. The company focuses on developing therapeutics for various conditions, including autoimmune diseases and infectious diseases, with several product candidates at different stages of clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
conferences
Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) has commenced its Phase 3 RESILIENT study for TNX-102 SL, targeting fibromyalgia management. This pivotal study follows positive results from the earlier Phase 3 RELIEF study, which showed significant efficacy (p=0.010), while the subsequent RALLY study did not achieve significance (p=0.115). An interim analysis of RESILIENT is anticipated in Q1 2023. The investigational TNX-102 SL aims to provide a non-addictive treatment option for fibromyalgia, a condition afflicting an estimated 6-12 million adults in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
-
Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) announced FDA clearance for a Phase 2 clinical trial of TNX-102 SL, targeting Long COVID patients with symptoms overlapping fibromyalgia. This trial will evaluate the efficacy of TNX-102 SL, a sublingual formulation, in treating multi-site pain associated with Long COVID. The 14-week study aims to enroll approximately 470 patients across 30 sites, with results anticipated to inform on pain intensity changes. Long COVID affects over 30% of those recovering from COVID-19, presenting a significant health concern.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
covid-19
-
Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) has announced a new preclinical research agreement with Kansas State University to advance the development of TNX-2300, a live virus vaccine aimed at protecting against COVID-19. This vaccine uses a bovine parainfluenza virus vector platform and aims to enhance T cell immunity through the co-expression of the CD40-ligand. Initial studies show that this vaccine could elicit strong and durable immunity. The research is directed by Dr. Waithaka Mwangi, and an exclusive license for the vaccine's clinical and commercial use has been granted to Tonix.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
covid-19
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that its CEO Seth Lederman will present at the 2022 Virtual Growth Conference, hosted by Maxim Group LLC from March 28-30, 2022. The presentations will be available on-demand through the conference portal. Tonix is focused on developing therapeutics for conditions such as fibromyalgia and Long COVID, with its lead candidates, TNX-102 SL and TNX-1300, expected to enter new phases of clinical trials in the first half of 2022. More information can be found on Tonix's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
conferences

FAQ

What is the current stock price of Tonix Pharmaceut (TNXP)?

The current stock price of Tonix Pharmaceut (TNXP) is $17.45 as of April 1, 2025.

What is the market cap of Tonix Pharmaceut (TNXP)?

The market cap of Tonix Pharmaceut (TNXP) is approximately 112.2M.

What is the core focus of Tonix Pharmaceuticals?

Tonix Pharmaceuticals focuses on developing, licensing, and commercializing innovative therapeutics that address significant public health challenges across areas such as CNS disorders, immunology, rare diseases, and infectious diseases.

How does Tonix generate its revenue?

The company generates revenue primarily through a combination of licensing its innovative therapeutics, strategic partnerships, and the commercialization of non-oral treatments that target unmet medical needs.

What are the main therapeutic areas Tonix is involved in?

Tonix is active in several therapeutic areas, including central nervous system disorders (like PTSD and fibromyalgia), immunological conditions such as transplant rejection and autoimmunity, as well as rare and infectious diseases.

How does Tonix's product portfolio differentiate itself?

Tonix differentiates its portfolio by focusing on innovative delivery methods, such as non-oral formulations like autoinjectors and nasal sprays, which can offer faster relief and improved patient convenience compared to traditional oral therapies.

What role does research and development play at Tonix?

Research and development are central to Tonix’s business model. The company invests in robust clinical trials and innovative scientific methods to evaluate and refine its broad pipeline, ensuring each product candidate meets high standards of efficacy and safety.

How does Tonix address the needs of patients with difficult-to-treat conditions?

By developing therapeutics that target conditions with significant unmet needs, such as rapid-acting migraine treatments and novel approaches for CNS and immunological disorders, Tonix aims to provide alternatives where traditional therapies have limited efficacy.

How does Tonix maintain regulatory compliance?

Tonix maintains regulatory compliance through meticulous clinical testing, dedicated R&D practices, and active engagement with regulatory agencies to ensure that its development processes and product candidates meet industry standards.

What challenges does Tonix face in its competitive landscape?

Tonix operates in a competitive biopharmaceutical market where traditional therapies and larger companies have established products. However, its focus on innovative, non-oral delivery systems and niche therapeutic areas helps it differentiate itself.
Tonix Pharmaceut

Nasdaq:TNXP

TNXP Rankings

TNXP Stock Data

112.24M
5.26M
3.32%
9.86%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHATHAM